{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:26:30Z","timestamp":1790195190311,"version":"4.1.0"},"reference-count":94,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The G-protein coupled receptors (GPCRs) belong to a large family of diverse receptors that are well recognized as pharmacological targets. However, very few of these receptors have been pursued as oncology drug targets. The Protease-activated receptor 1 (PAR1), which is a G-protein coupled receptor, has been shown to act as an oncogene and is an emerging anti-cancer drug target. In this paper, we provide an overview of PAR1\u2019s biased signaling role in metastatic cancers of the breast, lungs, and ovaries and describe the development of PAR1 inhibitors that are currently in clinical use to treat acute coronary syndromes. PAR1 inhibitor PZ-128 is in a Phase II clinical trial and is being developed to prevent ischemic and thrombotic complication of patients undergoing cardiac catheterization. PZ-128 belongs to a new class of cell-penetrating, membrane-tethered peptides named pepducins that are based on the intracellular loops of receptors targeting the receptor G-protein interface. Application of PZ-128 as an anti-metastatic and anti-angiogenic therapeutic agent in breast, lung, and ovarian cancer is being reviewed.<\/jats:p>","DOI":"10.3390\/ijms19082237","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T03:10:01Z","timestamp":1533093001000},"page":"2237","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach"],"prefix":"10.3390","volume":"19","author":[{"given":"Lidija","family":"Covic","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Tufts Medical Center, Boston, MA 02111, USA"},{"name":"Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA"},{"name":"Center for Hemostasis and Thrombosis Research, Tufts Medical Center, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Kuliopulos","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tufts Medical Center, Boston, MA 02111, USA"},{"name":"Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA"},{"name":"Center for Hemostasis and Thrombosis Research, Tufts Medical Center, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2018). Cancer Facts & Figures, American Cancer Society."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cell.2004.12.018","article-title":"PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells","volume":"120","author":"Boire","year":"2005","journal-title":"Cell"},{"key":"ref_3","first-page":"5933","article-title":"Signaling from Protease-activated Receptor-1 Inhibits Migration and Invasion of Breast Cancer Cells","volume":"61","author":"Kamath","year":"2001","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1158\/0008-5472.CAN-09-0187","article-title":"Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ajpath.2011.03.025","article-title":"Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer","volume":"179","author":"Cisowski","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/1535-7163.MCT-08-0177","article-title":"Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer","volume":"7","author":"Agarwal","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1158\/0008-5472.CAN-09-4341","article-title":"Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: Implications for antiangiogenic therapy","volume":"70","author":"Agarwal","year":"2010","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9826","DOI":"10.1038\/s41598-017-10377-z","article-title":"The Role of Na+\/Ca2+ Exchanger 1 in Maintaining Ductus Arteriosus Patency","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1073\/pnas.022460899","article-title":"Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides","volume":"99","author":"Covic","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1074\/jbc.R112.355461","article-title":"Turning receptors on and off with intracellular pepducins: New insights into G-protein-coupled receptor drug development","volume":"287","author":"Kuliopulos","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/ATVBAHA.114.303412","article-title":"G-protein-coupled receptors signaling pathways in new antiplatelet drug development","volume":"35","author":"Gurbel","year":"2015","journal-title":"Arterioscler. Thromb. Vas. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.112.091918","article-title":"Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin","volume":"126","author":"Zhang","year":"2012","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/ATVBAHA.115.306777","article-title":"Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease","volume":"36","author":"Gurbel","year":"2016","journal-title":"Arterioscler. Thromb. Vas. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/pr.54.2.203","article-title":"Proteinase-Activated Receptors","volume":"54","author":"Hollenberg","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Action","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/bi9824792","article-title":"Plasmin Desensitization of the PAR1 Thrombin Receptor: Kinetics, Sites of Truncation, and Implications for Thrombolytic Therapy","volume":"38","author":"Kuliopulos","year":"1999","journal-title":"Biochemistry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.chembiol.2003.10.014","article-title":"Structural basis for thrombin activation of a protease-activated receptor: Inhibition of intramolecular liganding","volume":"10","author":"Seeley","year":"2003","journal-title":"Chem. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cell.2009.02.018","article-title":"Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site","volume":"137","author":"Trivedi","year":"2009","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Austin, K.M., Covic, L., and Kuliopulos, A. (2012). Matrix metalloproteases and PAR1 activation. Blood.","DOI":"10.1182\/blood-2012-09-355958"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/0008-5472.CAN-05-2082","article-title":"Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells","volume":"66","author":"Nguyen","year":"2006","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"24330","DOI":"10.1074\/jbc.M112.356303","article-title":"Matrix metalloprotease-1a promotes tumorigenesis and metastasis","volume":"287","author":"Foley","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/onc.2013.157","article-title":"Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis","volume":"33","author":"Foley","year":"2013","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/jcp.24650","article-title":"Mouse matrix metalloprotease-1a (Mmp1a) gives new insight into MMP function","volume":"229","author":"Foley","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.0.CO;2-R","article-title":"Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in human fibroblasts and BC-8701 breast cancer cells","volume":"66","author":"Rutter","year":"1997","journal-title":"J. Cell. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1074\/jbc.M112.439893","article-title":"Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses","volume":"288","author":"Folgueras","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23105","DOI":"10.1074\/jbc.M113.467019","article-title":"Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis","volume":"288","author":"Austin","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1161\/CIRCULATIONAHA.111.066787","article-title":"Beta-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells","volume":"125","author":"Jaffre","year":"2012","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-014-0282-0","article-title":"Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver","volume":"14","author":"Mendonsa","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_29","first-page":"1119","article-title":"MMP13 is potentially a new tumor marker for breast cancer diagnosis","volume":"22","author":"Chang","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/blood-2012-08-452169","article-title":"Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46","volume":"120","author":"Mosnier","year":"2012","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fendo.2014.00067","article-title":"Biased signaling of protease-activated receptors","volume":"5","author":"Zhao","year":"2014","journal-title":"Front. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cierna, Z., Mego, M., Janega, P., Karaba, M., Minarik, G., Benca, J., and Pindak, D. (2014). Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-472"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-005-9042-6","article-title":"Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer","volume":"95","author":"Przybylowska","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1189\/jlb.0607338","article-title":"Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation","volume":"82","author":"Libert","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: Regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrm2125","article-title":"Matrix metalloproteinases and the regulation of tissue remodelling","volume":"8","author":"Ewald","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature11701","article-title":"High-resolution crystal structure of human protease-activated receptor 1","volume":"492","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"15785","DOI":"10.1074\/jbc.M115.636316","article-title":"Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics","volume":"290","author":"Zhang","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-1-4939-2806-4_13","article-title":"Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics","volume":"1324","author":"Zhang","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1074\/jbc.M509525200","article-title":"The Role of the PAR1 Receptor 8th Helix in Signaling: The 7-8-1 receptor activation mechanism","volume":"278","author":"Swift","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/onc.2015.217","article-title":"Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2","volume":"35","author":"Yang","year":"2015","journal-title":"Oncogene"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104855","DOI":"10.18632\/oncotarget.20418","article-title":"Doxycycline inhibits breast cancer EMT and metastasis through PAR-1\/NF-kappaB\/miR-17\/E.-cadherin pathway","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"24606","DOI":"10.1038\/srep24606","article-title":"Twist-mediated Epithelial-mesenchymal Transition Promotes Breast Tumor Cell Invasion via Inhibition of Hippo Pathway","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1038\/ncomms9853","article-title":"PH motifs in PAR1&2 endow breast cancer growth","volume":"6","author":"Kancharla","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1074\/jbc.RA117.001516","article-title":"The alpha-arrestin ARRDC3 suppresses breast carcinoma invasion by regulating G protein-coupled receptor lysosomal sorting and signaling","volume":"293","author":"Arakaki","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00535-017-1329-y","article-title":"ALEX1, a novel tumor suppressor gene, inhibits gastric cancer metastasis via the PAR-1\/Rho GTPase signaling pathway","volume":"53","author":"Pang","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"ra55","DOI":"10.1126\/scisignal.2002006","article-title":"Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration","volume":"4","author":"Hatziapostolou","year":"2011","journal-title":"Sci. Signal."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17689","DOI":"10.1074\/jbc.M113.536227","article-title":"The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth","volume":"289","author":"Sayyah","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18412","DOI":"10.1074\/jbc.M114.628156","article-title":"Endothelial Angiogenesis and Barrier Function in Response to Thrombin Require Ca2+ Influx through the Na+\/Ca2+ Exchanger","volume":"290","author":"Andrikopoulos","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/0008-5472.CAN-12-4495","article-title":"Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination","volume":"73","author":"Deryugina","year":"2013","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1158\/0008-5472.CAN-15-0964","article-title":"Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen","volume":"75","author":"Adams","year":"2015","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/ijc.30862","article-title":"TGF-beta induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1479-5876-7-47","article-title":"PAR1 is selectively over expressed in high grade breast cancer patients: A cohort study","volume":"7","author":"Hernandez","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35000034","article-title":"The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells","volume":"2","author":"Batlle","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2131","article-title":"Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?","volume":"7","author":"Peinado","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/nar\/gkg403","article-title":"Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene","volume":"31","author":"Ferguson","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature12785","article-title":"HMGA2 functions as a competing endogenous RNA to promote lung cancer progression","volume":"505","author":"Kumar","year":"2014","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/jid.2014.480","article-title":"IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma","volume":"135","author":"Sheen","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/1541-7786.MCR-14-0363","article-title":"MUC1-C Induces the LIN28B-->LET-7-->HMGA2 Axis to Regulate Self-Renewal in NSCLC","volume":"13","author":"Alam","year":"2015","journal-title":"Mol. Cancer Res. (MCR)"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"33437","DOI":"10.1074\/jbc.M802016200","article-title":"HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition","volume":"283","author":"Thuault","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1242\/jcs.142539","article-title":"Alpha-arrestins\u2014New players in Notch and GPCR signaling pathways in mammals","volume":"127","author":"Puca","year":"2014","journal-title":"J. Cell Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1124\/mol.109.056622","article-title":"Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates","volume":"76","author":"Holinstat","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1038\/onc.2008.84","article-title":"Persistent transactivation of EGFR and ErbB2\/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion","volume":"27","author":"Arora","year":"2008","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"19700","DOI":"10.3390\/ijms151119700","article-title":"Cell-surface receptors transactivation mediated by g protein-coupled receptors","volume":"15","author":"Cattaneo","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wang, H., and Zhang, X. (2017). Magnetic Fields and Reactive Oxygen Species. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102175"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/emmm.201100145","article-title":"A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis","volume":"3","author":"Tressel","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ni1525","article-title":"\u2018Role reversal\u2019 for the receptor PAR1 in sepsis-induced vascular damage","volume":"8","author":"Kaneider","year":"2007","journal-title":"Nat Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1073\/pnas.1017091108","article-title":"Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins","volume":"108","author":"Sevigny","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Miller, J., Agarwal, A., Devi, L.A., Fontanini, K., Hamilton, J.A., Pin, J.P., and Hunt III, S.W. (2009). Insider access: Pepducin symposium explores a new approach to GPCR modulation. Ann. N. Y. Acad. Sci., 1180.","DOI":"10.1111\/j.1749-6632.2009.05326.x"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nm1245","article-title":"Reversing Systemic Inflammatory Response Syndrome with Chemokine Receptor Pepducins","volume":"11","author":"Kaneider","year":"2005","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lfs.2003.09.012","article-title":"Blocking receptors on the inside: Pepducin-based intervention of PAR signaling and thrombosis","volume":"74","author":"Kuliopulos","year":"2003","journal-title":"Life Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1749-6632.2011.06039.x","article-title":"G protein-coupled receptor modulation with pepducins: Moving closer to the clinic","volume":"1226","author":"Dimond","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_74","unstructured":"Langel, U. (2007). Pharmacology and in vivo efficacy of pepducins in hemostasis and arterial thrombosis. Handbook of Cell-Penetrating Peptides, Taylor & Francis. [2nd ed.]."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2011-04-347518","article-title":"Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia","volume":"119","author":"Lee","year":"2012","journal-title":"Blood."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"22255","DOI":"10.1073\/pnas.1009633108","article-title":"Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells","volume":"107","author":"Tchernychev","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"15878","DOI":"10.1021\/ja206661w","article-title":"Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4","volume":"133","author":"Janz","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/ATVBAHA.118.310967","article-title":"Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis","volume":"38","author":"Rana","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1055\/s-0037-1613071","article-title":"Role of the PAR4 Thrombin Receptor in Stabilizing Platelet-Platelet Aggregates as revealed by a Patient with Hermansky-Pudlak Syndrome","volume":"87","author":"Covic","year":"2002","journal-title":"Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm0898-909","article-title":"Thrombin Receptor Overexpression in Malignant and Physiological Invasion Processes","volume":"4","author":"Uziely","year":"1998","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.1074\/jbc.M007027200","article-title":"Tumor Cell Invasion Is Promoted by Activation of Protease Activated Receptor-1 in Cooperation with the alpha vbeta 5 Integrin","volume":"276","author":"Maoz","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/MCB.15.2.704","article-title":"Expression Cloning of Oncogenes by Retroviral Transfer of cDNA Libraries","volume":"15","author":"Whitehead","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/sj.onc.1204281","article-title":"The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways","volume":"20","author":"Martin","year":"2001","journal-title":"Oncogene"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1096\/fj.02-0316com","article-title":"Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation","volume":"17","author":"Yin","year":"2003","journal-title":"FASEB J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CMAR.S40601","article-title":"Presentation and management of docetaxel-related adverse effects in patients with breast cancer","volume":"6","author":"Ho","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3816\/CLC.2006.n.023","article-title":"Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer","volume":"7","author":"Ghio","year":"2006","journal-title":"Clin. Lung Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: Bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the Secondary Prevention of Atherothrombotic Events","volume":"366","author":"Morrow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_90","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: Lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","article-title":"Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: The lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial","volume":"123","author":"Bhatt","year":"2011","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.ijcard.2012.08.014","article-title":"Novel oral anticoagulants in acute coronary syndrome","volume":"167","author":"Costopoulos","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11239-012-0750-6","article-title":"Atopaxar and its effects on markers of platelet activation and inflammation: Results from the LANCELOT CAD program","volume":"34","author":"Bhatt","year":"2012","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","article-title":"Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin\u2014Coronary Artery Disease Trial","volume":"123","author":"Wiviott","year":"2011","journal-title":"Circulation"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/8\/2237\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:15:30Z","timestamp":1760195730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/8\/2237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":94,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["ijms19082237"],"URL":"https:\/\/doi.org\/10.3390\/ijms19082237","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]}}}